Search Results
Your search for ,twO matches 12067 pages
Showing 4651 - 4700AACR Annual Meeting to Be Held in Two-Part Virtual Platform
Earlier this month, the American Association for Cancer Research (AACR) announced that the group’s Annual Meeting would be held in a two-part virtual format and not in person. Instead, segments of the meeting program will be presented in late April and in June 2020. The decision was made not to...
EXPECT INTEREST AND QUESTIONS ABOUT STATINS AND METFORMIN
A study showing that statins used alone or in combination with metformin was associated with reduced prostate cancer mortality and all-cause mortality among men with high-risk prostate cancer may raise more questions about these already commonly used drugs.1 “Metformin is the first-line therapy for ...
Statins With or Without Metformin Are Associated With Increased Survival in Patients With High‑Risk Prostate Cancer
A population-based retrospective cohort study involving 12,700 patients found that men with high-risk prostate cancer who took a statin alone or in combination with metformin had reduced all-cause and prostate cancer–specific mortality. The associations between the medications and reduced...
Nivolumab/Ipilimumab in Patients With Sorafenib-Pretreated Hepatocellular Carcinoma
On March 10, 2020, the combination of nivolumab (Opdivo) and ipilimumab (Yervoy) was granted accelerated approval for treatment of patients with hepatocellular carcinoma who have been previously treated with sorafenib.1-3 Supporting Efficacy Data The approval was based on findings in a cohort...
Inoperable Carcinoma of the Breast
The text and photograph here are excerpted from a four-volume series of books titled Oncology: Tumors & Treatment, A Photographic History, The X-Ray Era: 1901–1915 by Stanley B. Burns, MD, FACS, and Elizabeth A. Burns. The photograph appears courtesy of Dr. Burns and The Burns Archive. To view ...
Chemotherapy and the Sweat Lodge
The ASCO Post is pleased to reproduce installments of Art of Oncology as published previously in the Journal of Clinical Oncology. These articles focus on the experience of suffering from cancer or of caring for people diagnosed with cancer, and they include narratives, topical essays, historical...
Survey of Patients’ Experience With Radiation Therapy for Cancer Finds Some Gaps in Expectation vs Reality
In a study reported in JCO Oncology Practice, Narek Shaverdian, MD, of Memorial Sloan Kettering Cancer Center, New York, and colleagues found that most patients undergoing radiation therapy for cancer reported that anticipated adverse effects did not occur or were no worse than expected.1 However, ...
After Training Across Three Continents, a Hematologist Leads the Wisconsin Hematology/Oncology Division
In this edition of Living a Full Life, guest editor Jame Abraham, MD, FACP, spoke with hematologist Parameswaran Hari, MD, MRCP, Chief of the Division of Hematology and Oncology at the Medical College of Wisconsin, Milwaukee. In addition, Dr. Hari holds the Armand J. Quick/William F. Stapp Chair...
ELEVATE-TN: Acalabrutinib With or Without Obinutuzumab vs Chlorambucil/Obinutuzumab in Patients With Previously Untreated CLL
As reported in The Lancet by Jeff P. Sharman, MD, and colleagues, the phase III ELEVATE-TN trial showed significantly improved progression-free survival with both acalabrutinib/obinutuzumab and acalabrutinib monotherapy vs chlorambucil/obinutuzumab in patients with treatment-naive chronic...
FDA Approves Sacituzumab Govitecan-hziy for Patients With Previously Treated Metastatic Triple-Negative Breast Cancer
On April 22, the U.S. Food and Drug Administration (FDA) approved sacituzumab govitecan-hziy (Trodelvy) for the treatment of adult patients with metastatic triple-negative breast cancer who have received at least two prior therapies for metastatic disease. Sacituzumab govitecan-hziy is the first...
Anti-CD22 CAR T-Cell Therapy for CD22-Positive B-Cell Malignancies
In an update of a phase I trial of anti-CD22 chimeric antigen receptor (CAR) T-cell therapy in children and young adults with relapsed or refractory CD22-positive B-cell malignancies reported in the Journal of Clinical Oncology, Shah et al described findings in cohorts receiving treatment at doses...
April Is the Cruelest Month
April is the cruelest month, breeding Lilacs out of the dead land, mixing Memory and desire, stirring Dull roots with spring rain. Winter kept us warm, covering Earth in forgetful snow, feeding A little life with dried tubers. —T.S. Eliot, The Burial of the Dead, The Waste Land, 1922 I started...
Quantitative Microelastography for Tumor Detection in Breast-Conserving Surgical Margins
A high-resolution, three-dimensional imaging technique, when combined with quantitative measurement of tissue elasticity, could accurately detect cancer within the resected margins of surgical specimens taken from patients undergoing breast-conserving surgery, according to a study published by...
A Segregated-Team Workflow Model During the COVID-19 Pandemic in a Cancer Center
In an article published in Annals of Oncology, members of the National University Cancer Institute of Singapore (NCIS) workflow team described a segregated-team workflow model that allowed continuation of cancer care at the comprehensive cancer center during the COVID-19 outbreak in Singapore....
Aspirin Use and Risk of Cancers of the Digestive Tract
Aspirin may be associated with a reduction in the risk of developing several cancers of the digestive tract. The largest and most comprehensive analysis to date of the link between aspirin and digestive tract cancers, published by Bosetti et al in Annals of Oncology, found reductions in the risk of ...
Durvalumab for Solid Tumors in Patients With Virologically Controlled HIV-1 Infection
In the Spanish phase II DURVAST trial reported in JAMA Oncology, Gonzalez-Cao et al found that treatment with durvalumab was feasible, safe, and active in patients with solid tumors and virologically controlled HIV-1 infection. As stated by the investigators, “Concerns about the safety and...
First-Line Durvalumab With or Without Tremelimumab vs Chemotherapy for Metastatic NSCLC: MYSTIC Study
As reported in JAMA Oncology by Naiyer A. Rizvi, MD, and colleagues, the phase III MYSTIC trial showed no overall survival benefit with durvalumab vs chemotherapy, or overall or progression-free survival benefit with durvalumab/tremelimumab vs chemotherapy, as first-line treatment in patients with...
Joint Publication Focuses on Clinical Practice Guidelines on Opioid Use for Pain Management
A recently published article by Schatz et al offers new clarity around the use of prescription opioids in pain management for people with a diagnosis or history of cancer and chronic pain. The joint publication, which appeared in both JNCCN—Journal of the National Comprehensive Cancer Network and...
Immune Checkpoint Inhibitor Treatment for Patients With Cancer During the COVID-19 Pandemic
In an article published in the journal Immunotherapy, Melissa Bersanelli, MD, of the Medical Oncology Unit, University Hospital of Parma, Italy, discusses controversies regarding the use of immune checkpoint inhibitor therapy in patients with cancer during the COVID-19 pandemic, suggesting that...
Neoadjuvant Immunotherapy in Early-Stage Colon Cancer
Patients with localized colon cancer may benefit from a short course of neoadjuvant immunotherapy, according to findings from the exploratory phase II NICHE study published by Myriam Chalabi, MD, and colleagues in Nature Medicine. Study Results Forty patients with two colon cancer subtypes—either ...
Activity of Pembrolizumab in Patients With NSCLC Brain Metastases
As reported in The Lancet Oncology by Sarah B. Goldberg, MD, MPH, and colleagues, continued follow-up of the non–small cell lung cancer (NSCLC) cohort of a single-institution phase II trial showed that pembrolizumab produced responses in patients with brain metastases and programmed cell death...
FDA Pipeline: Priority Reviews for Immunotherapy Based on Biomarker Status, Combination First-Line Therapy in Lung Cancer
Over the past week, the U.S. Food and Drug Administration (FDA) granted Priority Review to an immunotherapeutic agent for solid tumors with a high tumor mutational burden and to a combination treatment for the first-line treatment of metastatic or recurrent non–small cell lung cancer. The agency...
‘Textbook Outcome’ in Patients Undergoing Resection of Pancreatic Neuroendocrine Tumors
In a study reported in the Journal of Surgical Oncology, Timothy M. Pawlik, MD, MPH, PhD, and colleagues found that approximately half of patients undergoing resection of pancreatic neuroendocrine tumors (PNETs) had a “textbook outcome”—a result associated with significantly improved disease-free...
Outcomes of COVID-19 Infection in Patients With Cancer in Wuhan, China
In a retrospective cohort study reported in the Annals of Oncology, Li Zhang, MD, of the Department of Oncology, Tongji Hospital, Huazhong University of Science and Technology, Wuhan, China, and colleagues described characteristics and outcomes of COVID-19 infection in 28 patients with cancer from...
International Palliative Care Workshop in Russia Educates Providers, Improves Care Across Region
ASCO, in collaboration with international oncology societies, hosts International Palliative Care Workshops (IPCWs) designed to teach participants practical skills in patient communication and the management of cancer symptoms and pain. The IPCWs are led by ASCO member volunteers and local experts...
Living A Full Life After Pancreatic Cancer
I have been a radiologic technologist for 47 years, so after going to the bathroom one Sunday morning in October 2018 and finding my urine had suddenly turned dark, I knew something was wrong. I wasn’t in any pain and did not have a urinary tract infection, which would explain the discoloration of...
A Hallmark Moment
The ASCO Post is pleased to reproduce installments of the Art of Oncology as published previously in the Journal of Clinical Oncology. These articles focus on the experience of suffering from cancer or of caring for people diagnosed with cancer, and they include narratives, topical essays,...
Highlights From Transplantation and Cellular Therapy Meetings of ASTCT and CIBMTR
The Combined Annual Meetings of the American Society for Transplantation and Cellular Therapy (ASTCT) and the Center for International Blood & Marrow Transplant Research (CIBMTR) were held in Orlando, Florida, from February 19–23, 2020. The scientific program addressed the most timely issues in ...
Updates From Selected Clinical Trials in Breast Cancer
Each year, The ASCO Post asks Jame Abraham, MD, FACP, Chairman of the Department of Hematology and Medical Oncology at Taussig Cancer Institute and Professor of Medicine at the Cleveland Clinic Lerner College of Medicine, to offer his picks for the most important research presented at 2019 San...
Inspired by Her Physician Father, Reshma Jagsi, MD, DPhil, Tirelessly Advocates for Women’s Health and Careers in Medicine
Physician-scientist, Reshma Jagsi, MD, DPhil, was encouraged by her parents to become a politically active, socially conscious citizen of the world. “As a young woman, my mother traveled from Africa on a scholarship to the United States, where she attended the University of Wisconsin. It was in the ...
SEMA4D Inhibition: A Novel Means of Improving Immune Response
A novel class of inhibitors may hold some promise for boosting responses to checkpoint inhibitors and for sensitizing poorly immunogenic tumors, such as pancreatic cancer, to immunotherapy. The drug targets semaphorin 4D (SEMA4D), a glycoprotein expressed on the cell membranes of many tumor types....
Pembrolizumab Plus Radiotherapy Worthy of Further Study in Locally Advanced Squamous Cell Head and Neck Cancer
The combination of the checkpoint inhibitor pembrolizumab and definitive radiation therapy appears to be a safe and feasible option for patients with locally advanced head and neck cancer who are not eligible for cisplatin, according to data presented at the 2020 Multidisciplinary Head and Neck...
T-Cell Responses and Benefit From Treatment With Ipilimumab in Patients With Metastatic Castration-Resistant Prostate Cancer
Although patients with metastatic castration-resistant prostate cancer typically have limited responses to immunotherapy, a subset of patients with pretreatment evidence of active T-cell responses in their tumors experienced prolonged survival following treatment with ipilimumab in a phase II...
New Prognostic Score for Asymptomatic Patients With Early-Stage CLL
A new prognostic tool may help to predict time to first treatment for patients with early-stage, asymptomatic chronic lymphocytic leukemia (CLL). Researchers described what they hope will become a point-of-care resource to help improve clinical decision-making in a study published by Rossi et al in ...
PSA Levels Before Salvage Radiotherapy and Outcomes With Long-Term Antiandrogen Therapy in Prostate Cancer
In an analysis from the NRG/RTOG 9601 trial reported in JAMA Oncology, Daniel E. Spratt, MD, and colleagues found that higher prostate-specific antigen (PSA) pre–salvage radiotherapy (SRT) levels after prostatectomy were associated with better overall survival vs lower levels in men with prostate...
FDA Approves Encorafenib/Cetuximab for BRAF V600E–Mutated Metastatic Colorectal Cancer
On April 8, the U.S. Food and Drug Administration (FDA) approved encorafenib (Braftovi) in combination with cetuximab (Erbitux) for the treatment of pretreated adult patients with metastatic colorectal cancer with a BRAF V600E mutation detected by an FDA-approved test. BEACON CRC Efficacy was...
Brief Highlights on Novel Therapies for Prostate, Bladder, and Kidney Cancers
Attendees gathered at the 2020 Genitourinary Cancers Symposium in San Francisco to hear the latest news about treating patients with cancers of the prostate, bladder, kidneys, and testicles. In addition to the comprehensive coverage of the meeting in The ASCO Post, here are some brief highlights...
Pediatric Cancer Investment Needs and Benefits: Findings From a Commission Created by The Lancet Oncology
Improving care for children with cancer worldwide could bring a triple return on investment and prevent millions of deaths, according to a new Commission report published by Atun et al in The Lancet Oncology. Without additional investment in childhood cancer care, new estimates produced for the...
Case Study: Patient With Multiple Myeloma Treated for COVID-19 With Tocilizumab
A case study of one patient with multiple myeloma diagnosed with COVID-19 in Wuhan, China, published by Zhang et al in Blood Advances examined the efficacy of the immunosuppressant tocilizumab as a treatment for this particular patient. The report also suggested that patients with hematologic...
$20 Million in Grants Awarded to Identify Therapies for COVID-19
The partners in the COVID-19 Therapeutics Accelerator—a large-scale initiative launched by the Bill & Melinda Gates Foundation, Wellcome, and Mastercard—awarded $20 million in initial grants to three institutions. The University of Washington, the University of Oxford, and La Jolla Institute...
Daratumumab for Relapsed or Refractory Multiple Myeloma: Subcutaneous vs Intravenous Dosing
Findings from the phase III COLUMBA trial have shown that subcutaneous daratumumab is not inferior to intravenous daratumumab in terms of efficacy and pharmacokinetics and had an improved safety profile in patients with relapsed or refractory multiple myeloma. These results were published by...
Methylation Signatures From Sequencing Circulating Cell-Free DNA Detected Different Types of Cancer Across Multiple Stages
Researchers have developed the first blood test that can accurately detect more than 50 types of cancer and identify in which tissue the cancer originated—often before there are any clinical signs or symptoms of the disease. These findings were published by Liu et al in Annals of Oncology. In their ...
KTE-X19 for Relapsed or Refractory Mantle Cell Lymphoma: ZUMA-2 Trial
In a phase II trial reported in The New England Journal of Medicine, Michael Wang, MD, and colleagues found that the anti-CD19 chimeric antigen receptor (CAR) T-cell therapy KTE-X19 produced a high response rate in patients with relapsed or refractory mantle cell lymphoma who had received previous...
Clinical Trials to Evaluate Activity of Biologics, Other Agents Against COVID-19
In an effort to expedite research for agents with potential activity against symptoms associated with the novel coronavirus (COVID-19), the U.S. Food and Drug Administration (FDA) is evaluating and/or has approved a number of randomized clinical trials seeking to determine whether a drug has...
AACR Annual Meeting 2020 to Be Held in a Virtual-Only Format
Today, the American Association for Cancer Research (AACR) Board of Directors issued the following announcement: The AACR has been closely monitoring the rapid escalation of the COVID-19 pandemic. The health and safety of all Annual Meeting attendees and the patients and communities they serve are...
FDA Approves Luspatercept-aamt for Second-Line Treatment of Anemia in Adult Patients With Myelodysplastic Syndromes
On April 3, the U.S. Food and Drug Administration (FDA) approved luspatercept-aamt (Reblozyl) for the treatment of anemia that fails to respond to an erythropoiesis-stimulating agent and requires two or more red blood cell units over 8 weeks in adult patients with very low- to intermediate-risk...
Harvard Medical Student’s Innovation: Disinfection You Can See
In 2014, three undergrads at Columbia University had a crazy idea for a hackathon challenge: colorize bleach so health-care workers could spot missed areas on the surfaces and personal protective equipment they are trying to disinfect. Five years later, the result is a product called Highlight®,...
FDA Pipeline: Approval of New Dosing for Biosimilar, Plus Two Fast Track Designations
The U.S. Food and Drug Administration (FDA) recently approved a new dose for a biosimilar referencing trastuzumab and granted Fast Track designations to agents for patients with urothelial cancer and follicular lymphoma. Approval of Multidose Vial of Trastuzumab Biosimilar The FDA approved a...
Oncologists on the Front Lines of the COVID-19 Pandemic: A Conversation With Miriam A. Knoll, MD
During the coronavirus disease 2019 (COVID-19) pandemic, The ASCO Post will be interviewing oncologists on how they and their centers are dealing with the crisis. Here, we speak with Miriam A. Knoll, MD, a radiation oncologist at the John Theurer Cancer Center, Hackensack University Medical Center, ...
Pembrolizumab in Previously Treated Metastatic High-Grade Neuroendocrine Neoplasms
As reported in the British Journal of Cancer by Namrata Vijayvergia, MD, and colleagues, a pooled analysis of two phase II studies found that pembrolizumab monotherapy showed little activity in patients with previously treated metastatic high-grade neuroendocrine neoplasms. Study Details In the...
